Regeneron Pharmaceuticals: Q2 Earnings Insights

 

Shares of Regeneron Pharmaceuticals REGN moved higher by 0.0% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 260.34% year over year to $25.80, which beat the estimate of $17.69.

Revenue of $5,139,000,000 up by 163.27% year over year, which beat the estimate of $3,890,000,000.

Outlook

Regeneron lowered FY21 R&D spending guidance from $2.7 billion-$2.85 billion to $2.65 billion-$2.75 billion.

Conference Call Details

Date: Aug 05, 2021

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/j6cw2spu

Price Action

52-week high: $660.00

Company's 52-week low was at $441.00

Price action over last quarter: Up 16.96%

Company Description

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!